Results 161 to 170 of about 7,988 (196)
Integrated bioprocessing and genetic strategies to enhance soluble expression of anti-HER2 immunotoxin in E. Coli. [PDF]
AMB ExpressMani S, Arab B, Akbari V, Chou CP.
europepmc +1 more source
Therapeutic Promise and Biotechnological Prospects of <i>Dendroaspis polylepis</i> Venom Proteins: Mambalgins, Fasciculins, and Dendrotoxins. [PDF]
Int J Mol SciKowalczyk T +7 more
europepmc +1 more source
Ricin and Abrin in Biosecurity: Detection Technologies and Strategic Responses. [PDF]
Toxins (Basel)Zajaczkowski W +8 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Leukemia Research, 2005
Immunotoxins composed of cell-selective ligands covalently linked to peptide toxins have been developed for the treatment of chemotherapy relapsed or refractory malignancies including chronic lymphocytic leukemia (CLL). A number of CLL immunotoxins have been clinically tested including T101-ricin A, H65-ricin A, DAB(486)IL2, DAB(389)IL2, RFB4 (dsFv ...
Arthur E, Frankel, Robert J, Kreitman
openaire +2 more sources
Immunotoxins composed of cell-selective ligands covalently linked to peptide toxins have been developed for the treatment of chemotherapy relapsed or refractory malignancies including chronic lymphocytic leukemia (CLL). A number of CLL immunotoxins have been clinically tested including T101-ricin A, H65-ricin A, DAB(486)IL2, DAB(389)IL2, RFB4 (dsFv ...
Arthur E, Frankel, Robert J, Kreitman
openaire +2 more sources
Breast Cancer Research and Treatment, 1996
Pseudomonas exotoxin has been genetically modified so that it targets cancer cells. This was accomplished by deleting its cell binding domain and replacing it with Fv fragments of antibodies that react with breast, colon, and other cancers. Several recombinant immunotoxins are now in clinical trials.
I, Pastan +3 more
openaire +2 more sources
Pseudomonas exotoxin has been genetically modified so that it targets cancer cells. This was accomplished by deleting its cell binding domain and replacing it with Fv fragments of antibodies that react with breast, colon, and other cancers. Several recombinant immunotoxins are now in clinical trials.
I, Pastan +3 more
openaire +2 more sources
Expert Opinion on Pharmacotherapy, 2000
Immunotoxins are molecules which contain a protein toxin connected to a targeting antibody. The goal of therapy is for the molecule to bind selectively to cancer cells, or to cells mediating autoimmune disease, internalise and then for the toxin to kill the cell.
openaire +2 more sources
Immunotoxins are molecules which contain a protein toxin connected to a targeting antibody. The goal of therapy is for the molecule to bind selectively to cancer cells, or to cells mediating autoimmune disease, internalise and then for the toxin to kill the cell.
openaire +2 more sources
Neurosurgery Clinics of North America, 1996
Immunotoxins are extremely potent agents that recognize specific antigens located on metastatic tumor cells and cause cytotoxicity after cell entry by inhibiting protein synthesis. These agents have considerable in vitro efficacy against numerous metastatic tumor cell lines.
openaire +2 more sources
Immunotoxins are extremely potent agents that recognize specific antigens located on metastatic tumor cells and cause cytotoxicity after cell entry by inhibiting protein synthesis. These agents have considerable in vitro efficacy against numerous metastatic tumor cell lines.
openaire +2 more sources
Immunotoxins and nanobody-based immunotoxins: review and update
Journal of Drug Targeting, 2021Immunotoxins (ITs) are protein-based drugs that compose of targeting and cytotoxic moieties. After binding the IT to the specific cell-surface antigen, the IT internalises into the target cell and kills it. Targeting and cytotoxic moieties usually include monoclonal antibodies and protein toxins with bacterial or plant origin, respectively.
Mohammad Reza Khirehgesh +3 more
openaire +2 more sources
Annual Review of Immunology, 1996
The use of immunotoxins (ITs) in the therapy of cancer, graft-vs-host disease (GvHD), autoimmune diseases, and AIDS has been ongoing for the past two decades. ITs contain a targeting moiety for delivery and a toxic moiety for cytotoxicity. Theoretically, one molecule of a toxin, routed to the appropriate cellular compartment, will be lethal to a cell ...
G R, Thrush +3 more
openaire +2 more sources
The use of immunotoxins (ITs) in the therapy of cancer, graft-vs-host disease (GvHD), autoimmune diseases, and AIDS has been ongoing for the past two decades. ITs contain a targeting moiety for delivery and a toxic moiety for cytotoxicity. Theoretically, one molecule of a toxin, routed to the appropriate cellular compartment, will be lethal to a cell ...
G R, Thrush +3 more
openaire +2 more sources